AptinyxLogo_FullColor_RGB.jpg
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
November 12, 2019 07:27 ET | Aptinyx Inc.
200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line efficacy and safety data...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
November 05, 2019 08:07 ET | Aptinyx Inc.
EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
October 28, 2019 07:57 ET | Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
September 30, 2019 07:03 ET | Aptinyx Inc.
EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
September 26, 2019 08:07 ET | Aptinyx Inc.
EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
August 12, 2019 06:33 ET | Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
June 10, 2019 07:23 ET | Aptinyx Inc.
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with...
RND logo.PNG
Cannabidiol (CBD) Market To Reach USD 16.32 Billion By 2026 | Reports And Data
May 06, 2019 11:52 ET | Reports And Data
The growth of the market is driven by the increased R&D investment in the healthcare industry and rising acceptance of cannabis globally. Market Size – USD 1.04 Billion in 2018, Market Growth -...
New Alliances Push Inspire's Growth to 100 Partners, 750,000 Patients and Caregivers
May 11, 2016 07:00 ET | Inspire
ARLINGTON, VA--(Marketwired - May 11, 2016) -  Inspire, the leading social network for health, has added new nonprofit patient advocacy organizations -- including one focused on cancer...
Charlotte Chiropractor Recommends Acupuncture Treatments for Enhanced Pain Relief
December 09, 2012 10:00 ET | Omni Wellness Center
CHARLOTTE, N.C., Dec. 9, 2012 (GLOBE NEWSWIRE) -- Omni Wellness Center in Charlotte, NC is educating patients about the benefits of acupuncture. According to the wellness center, this treatment...